EDMONTON, AB

埃德蒙顿，艾伯塔省

,

，

Aug. 19, 2026

2026年8月19日

/PRNewswire/ -- Aurora Cannabis Inc. (the

/美通社/ -- Aurora Cannabis Inc.（

'Company'

“公司”

or

或者

'Aurora'

极光

) (NASDAQ:

) (纳斯达克：

ACB

ACB

) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy (the 'Companies').

（多伦多证券交易所代码：ACB）这家总部位于加拿大的全球领先医用大麻公司欣然宣布，已收购持牌进口商和批发商 Internode Pharma Limited 以及持牌药店 HAP Pharma Limited（统称“该公司”）。

Continue Reading

继续阅读

Quote from Aurora CEO, Miguel Martin

Aurora首席执行官Miguel Martin的引言

'The acquisition of Internode Pharma Limited and HAP Pharma Limited mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market. We believe that this transaction will allow us to fully leverage our operational, commercial and regulatory expertise to expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to UK patients,' said Miguel Martin, Executive Chairman and Chief Executive Officer of Aurora..

“收购Internode Pharma Limited和HAP Pharma Limited标志着Aurora的又一战略里程碑，因为我们继续有目的地投资，以扩大我们在快速增长的国际医用大麻市场中的领导地位。我们相信，此次交易将使我们能够充分利用我们的运营、商业和监管专业知识来扩大市场份额，同时也为英国患者提供稳定可靠的高质量医用大麻产品供应，”Aurora执行董事长兼首席执行官Miguel Martin表示。

'Given the growing patient demand, strong acceptance of our products and increasingly prescriptive regulatory standards, the UK represents an exciting opportunity for us, and acquiring these companies provides Aurora with greater agility to more reliably serve UK patients,' added Mr. Martin.

马丁先生补充道：“鉴于患者需求不断增长、市场对我们产品的认可度日益提升，以及监管标准日趋严格，英国为我们带来了令人振奋的机遇。通过收购这些公司，Aurora 将具备更强的敏捷性，从而更可靠地为英国患者提供服务。”

Strategic Rationale

战略理由

The UK is one of the largest European medical cannabis markets, representing a population of approximately 70 million people.

英国是欧洲最大的医用大麻市场之一，覆盖人口约7000万。

The Companies operate a licensed import and distribution facility and a virtual pharmacy in Birmingham, United Kingdom, providing Aurora with direct ownership and control of the supply chain from cultivation through to delivery to patients.

这些公司在英国伯明翰运营着一个持证的进口和分销设施以及一个虚拟药房，使Aurora能够直接拥有并控制从种植到向患者交付的整个供应链。

Aurora intends to leverage its commercial, regulatory and operational expertise to streamline distribution and drive market share gains in the rapidly growing UK medical cannabis market.

Aurora 打算利用其在商业、监管和运营方面的专业知识，简化分销流程，并在快速增长的英国医用大麻市场中提升市场份额。

This transaction is expected to be accretive to adjusted EBITDA contributions in future quarters due to operational efficiencies and reduced reliance on third parties to distribute Aurora's products to patients.

由于运营效率的提升以及减少对第三方分销Aurora产品给患者的依赖，预计该交易将在未来几个季度增加调整后的EBITDA贡献。

Aurora intends to evaluate further investment opportunities to expand distribution capacity in the UK to support increasing patient demand.

Aurora 计划评估进一步的投资机会，以扩大在英国的分销能力，满足日益增长的患者需求。

Transaction Details

交易详情

Aurora, through a wholly-owned subsidiary, indirectly purchased 100% of the shares of Internode Pharma Limited and HAP Pharma Limited. As consideration on closing, Aurora paid the selling shareholders GBP 2.1 million in cash, contingent on the satisfaction of certain conditions post-closing.

Aurora通过其全资子公司，间接收购了Internode Pharma Limited和HAP Pharma Limited的100%股份。作为交割对价，Aurora向出售股东支付了210万英镑现金，该支付以完成某些交割后条件为前提。

About Aurora

关于极光

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves both medical and consumer markets across Canada, Europe, Australia, and New Zealand, with a strategic focus on high-margin opportunities and a medical-first approach.

Aurora 是全球医用大麻领域的领导者，致力于通过科学专业知识、经证实的卓越表现以及对患者护理的深切承诺来改善人们的生活。Aurora 服务于加拿大、欧洲、澳大利亚和新西兰的医疗和消费市场，战略重点在于高利润机会和以医疗为先的方法。

Aurora's portfolio of trusted, leading brands includes Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, Tasty's® and Whistler Medical Marijuana Co.®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™..

Aurora 旗下拥有众多值得信赖的领先品牌，包括 Aurora®、MedReleaf®、Pedanios®、IndiMed™、San Raf®、Tasty's® 和 Whistler Medical Marijuana Co.®。凭借位于加拿大和德国的世界级 GMP 认证生产设施，以及一支行业领先的专业团队，Aurora 持续拓展其全球布局，致力于提供一致的高品质大麻产品，以实现“让大麻走向世界”™ 的使命。

Learn more at

了解更多

www.auroramj.com

www.auroramj.com

and follow us on

并在以下平台关注我们

X

X

and

和

LinkedIn

领英

.

。

Aurora's common shares trade on the NASDAQ and TSX under the symbol 'ACB'.

Aurora的普通股在纳斯达克和多伦多证券交易所上市，交易代码为“ACB”。

Forward Looking Information

前瞻性信息

This news release includes statements containing certain 'forward-looking information' within the meaning of applicable securities law ('forward-looking statements'). Forward-looking statements are frequently characterized by words such as 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur.

本新闻稿包含根据适用证券法定义的含有某些“前瞻性信息”的陈述（“前瞻性陈述”）。前瞻性陈述通常以“计划”、“继续”、“预期”、“预测”、“打算”、“相信”、“ anticipate ”、“估计”、“可能”、“将”、“潜在”、“提议”等类似词语为特征，或指出某些事件或条件“可能”或“将”发生。

Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's acquisition of Internode Pharma Limited and HAP Pharma Limited and related benefits to the business, including impacts on Adjusted EBITDA in future quarters, operational efficiencies and reduced reliance on third parties, and expectations for expanded distribution access to the UK medical cannabis market; the Company's ability to supply the UK market; the Company's plans to expand its leadership in the rapidly growing international medical cannabis market; the Company's competitive advantages in commercial, regulatory and operational expertise and its ability to leverage those advantages to drive market share; and statements regarding other growth and investment opportunities..

本新闻稿中包含的前瞻性陈述包括但不限于：关于公司收购Internode Pharma Limited和HAP Pharma Limited以及由此带来的业务益处的陈述，包括对未来季度调整后税息折旧及摊销前利润（Adjusted EBITDA）的影响、运营效率的提升以及对第三方依赖的降低；对扩大进入英国医用大麻市场分销渠道的预期；公司向英国市场供货的能力；公司计划在快速增长的国际医用大麻市场中扩大其领先地位；公司在商业、监管和运营专业知识方面的竞争优势，以及利用这些优势推动市场份额增长的能力；以及关于其他增长和投资机会的陈述。

These forward-looking statements are only predictions. Forward-looking information or statements contained in this news release have been developed based on the Company and its management's good faith assumptions relating to the financial, market, regulatory and other relevant environments that will exist and affect the Company's business and operations in the future.

这些前瞻性陈述仅为预测。本新闻稿中包含的前瞻性信息或陈述是基于本公司及其管理层本着诚信原则，就未来将存在并影响公司业务和运营的财务、市场、监管及其他相关环境所作出的假设而编制的。

Forward-looking information and statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management at the date the statements are made including, among other things, assumptions about: development costs remaining consistent with budgets; the ability to manage anticipated and unanticipated costs; access to favorable equity and debt capital markets; the ability to raise sufficient capital to advance the business of the Company; favorable operating and economic conditions; political and regulatory stability; obtaining and maintaining all required licenses and permits; receipt of governmental approvals and permits; sustained labour stability; stability in financial and capital goods markets; favorable production levels and costs from the Company's operations; the pricing of various cannabis products; the level of demand for cannabis products; the availability of third-party service providers and other inputs for the Company's operations; and the Company's ability to conduct operations in a safe, efficient, and effective manner.

前瞻性信息和陈述并非对未来表现的保证，而是基于管理层在作出这些陈述之日所作的多项估计和假设，其中包括但不限于以下假设：开发成本与预算保持一致；能够管理预期和非预期成本；进入有利的股权和债务资本市场；能够筹集足够资金以推进公司业务；良好的运营和经济条件；政治和监管稳定性；获得并维持所有必要的许可证和执照；获得政府批准和许可；持续的劳动力稳定；金融和资本货物市场的稳定；公司运营带来的有利生产水平和成本；各种大麻产品的定价；对大麻产品的需求水平；第三方服务提供商及其他投入品的可获得性；以及公司以安全、高效和有效的方式开展运营的能力。

The Company does not give any assurance that the assumptions on which forward-looking information or statements are based will prove to be correct, or that the Company's business or operations will not be affected in any material manner by these or other factors not foreseen or foreseeable by the Company or management or beyond th.

本公司不对以下事项提供任何保证：前瞻性信息或陈述所依据的假设将被证实为正确，或者本公司的业务或运营不会受到这些或其他因素的重大影响，而这些因素是本公司或管理层未能预见或无法预见的，或超出其控制范围的。

www.sedarplus.com

www.sedarplus.com

and filed with and available on the SEC's website at

并已提交至美国证券交易委员会（SEC）网站，可在该网站查阅

www.sec.gov

www.sec.gov

. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information.

. 本公司提醒，年度信息表（AIF）中所述的风险、不确定性和其他因素并非详尽无遗，其他因素也可能对其业绩产生不利影响。敦促读者在评估前瞻性陈述时仔细考虑相关风险、不确定性和假设，并 cautioned 不要过度依赖此类信息。

The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law..

本公司没有义务，并明确否认任何更新或修订任何前瞻性陈述的意图或义务，无论是否因新信息、未来事件或其他原因所致，除非适用的证券法明确要求。

Non-GAAP Measures

非公认会计准则指标

This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed 'Non-GAAP Measures'). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management.

本新闻稿提及某些未被国际财务报告准则（IFRS）认可或定义的财务绩效指标（称为“非公认会计准则指标”）。因此，这些数据可能无法与其他持牌大麻生产商及大麻公司所呈现的数据进行直接比较。非公认会计准则指标应与根据国际财务报告准则编制的其他数据一并考量，以便投资者能够以与Aurora管理层类似的方式评估公司的经营业绩、基础表现及前景。

Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading 'Cautionary Statement Regarding Certain Non-GAAP Performance Measures' in the FY27 Q1 MD&A is incorporated by reference into this news release.

因此，这些非公认会计准则财务指标旨在提供补充信息，协助管理层和投资者评估财务表现，不应孤立地看待或将其作为根据国际财务报告准则（IFRS）编制的业绩指标的替代。本新闻稿通过引用方式纳入了《2027财年第一季度管理层讨论与分析》中“关于某些非公认会计准则业绩指标的警示性声明”标题下的信息。

The MD&A is available on the Company's issuer profiles on SEDAR+ at .

管理层讨论与分析可在SEDAR+上的公司发行人档案中获取，网址为。

www.sedarplus.com

www.sedarplus.com

and on the U.S. Securities and Exchange Commission's (the 'SEC') EDGAR website at

以及在美国证券交易委员会（“SEC”）的EDGAR网站上，网址为

www.sec.gov

www.sec.gov

.

。

SOURCE Aurora Cannabis Inc.

来源：Aurora Cannabis Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示